2026 Dry Eye Pharmaceuticals Market Report: Global Analysis for 2025 to 2031, November, 2026

The “2026 Dry Eye Pharmaceuticals Market Report” delivers a comprehensive analysis of the evolving global market for dry eye therapeutics, examining the disease’s prevalence, diagnosis, treatment patterns, and commercial opportunities. The report provides detailed coverage of artificial tears, anti-inflammatory drops, miticides, tear evaporation inhibitors, mucin secretagogues, and other prescription and over-the-counter therapies. In-depth forecasts through 2031 quantify unit demand, sales revenue, and market growth across seven major global regions, providing critical insights into the trends and opportunities shaping this expanding market. 

Combining extensive market data with forward-looking analysis, the report examines the competitive landscape, emerging treatment approaches, innovative drug-delivery technologies, and a growing pharmaceutical pipeline poised to reshape dry eye care. Regional analyses explore differences in treatment adoption, regulatory environments, and market dynamics, while detailed company profiles highlight the product portfolios, strategic positioning, and competitive strengths of leading industry participants. 

The “2026 Dry Eye Pharmaceuticals Market Report” provides an in-depth examination of the global market for prescription and over-the-counter dry eye therapies, exploring the clinical, demographic, and commercial factors driving demand. Combining comprehensive disease analysis, treatment trends, competitive intelligence, and five-year forecasts through 2031, the report delivers actionable insights into market growth, emerging technologies, and opportunities across seven major global regions. 

The following topics are covered in the report: 

• Dry eye disease overview: Examination of tear film anatomy and function, disease mechanisms, symptoms, risk factors, diagnostic criteria, and DEWS classification. 
• Prevalence and risk analysis: Detailed estimates of dry eye prevalence, patient demographics, and risk factors across the US, Western Europe, Japan, China, India, Latin America, and other global markets. 
• Diagnosis and treatment trends: Analysis of diagnostic approaches, disease severity, regional practice patterns, and evolving standards of care influencing treatment decisions. 
• Treatment pathways and product segmentation: Comprehensive evaluation of artificial tears, anti-inflammatory therapies, miticides, tear evaporation inhibitors, mucin secretagogues, sustained-release treatments, and other emerging therapeutic options. 
• Global and regional market forecasts: Five-year projections through 2031 covering unit demand, sales revenue, product and competitor market shares, and treatment utilization trends across major geographic markets. 
• Pharmaceutical pipeline and innovation: Assessment of investigational therapies, emerging drug-delivery technologies, novel mechanisms of action, and late-stage products with the potential to reshape the competitive landscape. 
• Competitive landscape and company profiles: Detailed profiles of leading dry eye pharmaceutical manufacturers, examining product portfolios, development pipelines, commercial strategies, competitive positioning, and future growth opportunities. 

2 licensing types are available for this report:

• The price of the single-user license is $7,500.
• The price of the enterprise license is $11,250 (includes supplemental Excel file with all the tables and figures in the report, and report summary slides).

Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.

SINGLE USER LICENSE

• The Single User License allows for the use of a report by a single user within one corporate location.
• The report paper copy may not be reproduced (additional paper copies available for purchase).
• Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
• Only a single copy of the publication may be printed for internal use.
• Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

• The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
• Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
• Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Purchase price includes a printable PDF file of the report (purchasing organization may print multiple copies for use within the organization).
• Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.

Pay by credit card or by invoice.